(+)-Abscisic Acid

(+)-Abscisic Acid

SCHEMBL2590417

CC1=CC(=O)CC(C)(C)[C@@]1(O)/C=C\C(C)=C\C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 1.00
HIF1A Q16665 3/20 0.56
LANCL2 Q9NS86 1/20 0.46
RXRA P19793 13/20 0.42
RARG P13631 9/20 0.42
RXRB P28702 8/20 0.42
RXRG P48443 7/20 0.42
RARB P10826 7/20 0.41
ALDH1A1 P00352 4/20 0.36
RARA P10276 4/20 0.36
MAPT P10636 4/20 0.36
PTGS1 P23219 3/20 0.36
RORC P51449 2/20 0.36
CYP3A4 P08684 2/20 0.36
ADORA3 P0DMS8 2/20 0.36
MAPK1 P28482 2/20 0.36
HTR2B P41595 2/20 0.36
BLM P54132 2/20 0.36
NR4A1 P22736 1/20 0.36
NR1H2 P55055 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(+)-Abscisic Acid SCHEMBL2590419 1.00 TSHR (1.00) TSHRHIF1ALANCL2RXRARARG
(+)-Abscisic Acid SCHEMBL11994582 1.00 TSHR (1.00) TSHRHIF1ALANCL2RXRARARG
(+)-Abscisic Acid SCHEMBL2590414 1.00 TSHR (1.00) TSHRHIF1ALANCL2RXRARARG
(+)-Abscisic Acid SCHEMBL15042784 1.00 TSHR (1.00) TSHRHIF1ALANCL2RXRARARG
(+)-Abscisic Acid SCHEMBL2591175 1.00 TSHR (1.00) TSHRHIF1ALANCL2RXRARARG
(+)-Abscisic Acid SCHEMBL2591173 1.00 TSHR (1.00) TSHRHIF1ALANCL2RXRARARG
(+)-Abscisic Acid SCHEMBL3107122 1.00 TSHR (1.00) TSHRHIF1ALANCL2RXRARARG
(+)-Abscisic Acid SCHEMBL33613 1.00 TSHR (1.00) TSHRHIF1ALANCL2RXRARARG
(+)-Abscisic Acid SCHEMBL14137764 1.00 TSHR (1.00) TSHRHIF1ALANCL2RXRARARG
(+)-Abscisic Acid SCHEMBL28818082 1.00 TSHR (1.00) TSHRHIF1ALANCL2RXRARARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150241448-A1 LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) 2015-08-27 US disclosed
US-20150241448-A1 LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) 2015-08-27 US disclosed
US-20150241448-A1 LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) 2015-08-27 US disclosed
US-9101573-B2 Lanthionine synthetase component C-like proteins as molecular targets for preventing and treating diseases and disorders VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) 2015-08-11 US disclosed
US-9101573-B2 Lanthionine synthetase component C-like proteins as molecular targets for preventing and treating diseases and disorders VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) 2015-08-11 US disclosed
US-9101573-B2 Lanthionine synthetase component C-like proteins as molecular targets for preventing and treating diseases and disorders VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) 2015-08-11 US disclosed
US-20110275558-A1 LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) 2011-11-10 US disclosed
US-20110275558-A1 LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) 2011-11-10 US disclosed
US-20110275558-A1 LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) 2011-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275558-A1 LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS LANCL2, ACSL1, LANCL1 TSHR 523/4885HIF1A 1154/4885LANCL2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.